Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Miravo Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.
Product Name : Blexten
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2022
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Miravo Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
